酒精性肝病发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2014.01.002

摘要/Abstract

摘要： 酒精性肝病（alcoholic liver disease,ALD）是指长期过量饮酒导致的肝脏疾病,包括酒精性脂肪肝（alcoholic fatty liver,AFL）、酒精性肝炎（alcoholic hepatitis,AH）、酒精性肝纤维化（alcoholic hepatic fibrosis,AHF）、酒精性肝硬化（alcoholic cirrhosis,AC）和肝细胞癌（hepatocellular carcinoma,HCC）。酒精性肝病是世界范围内慢性肝病的最重要病因之一,约占全球死亡率的3.8%,在发达国家十分常见。2007年美国国家防止酒精滥用及酒精中毒研究所的报告显示肝硬化死亡率位于死亡原因的第12位,其中超过48%的比例与酒精相关。在英国社区综合医院收治的各类肝硬化患者中,酒精性肝硬化占80%。在澳大利亚,酒精性肝硬化占总的疾病负担的5%,占肝病负担的50%,占肝移植病因的15%^[1]。在我国,随着社会经济的发展和生活水平的提高以及受“中国酒文化”的影响,ALD发病率呈逐渐上升的趋势,在某些地区已成为继病毒性肝炎之后导致肝损害的第二大病因^[2]。虽然饮酒是ALD的根本病因,90%~95%饮酒者可以发展为酒精性脂肪肝,但是只有30%~35%饮酒者发展为比较严重的酒精性肝病,包括酒精性肝炎、肝纤维化、肝硬化及肝细胞癌,说明除了酒精以外还有其他因素参与了ALD的发病机制^[3]。现从以下几方面简要介绍近几年国内外对ALD发病机制的研究进展。

关键词: 酒精性肝病, 发病机制, 危险因素

Key words: Alcoholic liver disease, Pathogenesis, Risk factors

王洪岩, 李鑫, 徐有青. 酒精性肝病发病机制研究进展^*[J]. 实用肝脏病杂志, 2014, 17(1): 5-8.

Wang Hongyan, Li Xin, Xu Youqing. Progress in the pathogenesis of alcoholic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 5-8.

参考文献

[1] Rehm JC,Mathers S,Popov A,et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet, 2009, 373（9682）：2223-2233.
[2] 任燚,肖庆贵,邬吉伟,等. 酒精性肝病临床流调现状. 现代保健·医学创新研究,2008,5（35）：55-56.
[3] Gao B,Bataller R. Alcoholic liver disease：pathogenesis and new therapeutic targets. Gastroenterology,2011,141（5）：1572-1585.
[4] Ramstedt M. Alcohol and suicide in 14 European countries. Addiction,2001,96（Suppl 1）：S59-S75.
[5] Corrao GV,Bagnardi A,Zambon A,et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med,2004,38（5）：613-619.
[6] Kechagias S,Zanjani S,Gjellan S,et al. Effects of moderate red wine consumption on liver fat and blood lipids：a prospective randomized study. Ann Med,2011,43（7）：545-554.
[7] Zhou JY,Jiang ZA,Zhao CY,et al. Long-term binge and escalating ethanol exposure causes necroinflammation and fibrosis in rat liver. Alcohol Clin Exp Res,2013,37（2）：213-222.
[8] Shearn CT,Smathers RL,Jiang H,et al. Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis. J Nutr Biochem,2013,24（8）：1436-1445.
[9] Seth D,Haber PS,Syn WK,et al. Pathogenesis of alcohol-induced liver disease：classical concepts and recent advances. J Gastroenterol Hepatol,2011,26（7）：1089-1105.
[10] Stickel F,Hampe J. Genetic determinants of alcoholic liver disease. Gut,2012,61（1）：150-159.
[11] Xu JK,Lai K,Verlinsky A,et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol,2011,55（3）：673-682.
[12] Szabo G,Wands JR,Eken A,et al. Alcohol and hepatitis C virus—interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res,2010,34（10）：1675-1686.
[13] Mello T,Ceni E,Surrenti C,et al. Alcohol induced hepatic fibrosis：role of acetaldehyde. Mol Aspects Med,2008,29（1-2）：17-21.
[14] Kendrick SF,O'Boyle G,Mann J,et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology,2010,51（6）：1988-1997.
[15] Cruz A,Muntane J. Alcoholic liver disease,oxidative stress, and antioxidants. Rev Esp Enferm Dig,2011,103（8）：393-395.
[16] Harrison-Findik DD,Schafer D,Klein E,et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem,2006,281（32）：22974-22982.
[17] Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med,2008,29（1-2）：9-16.
[18] Sozio MD,Crabb W. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab,2008,295（1）：E10-16.
[19] Bardag-Gorce F,French BA,Nan L,et al. CYP2E1 induced by ethanol causes oxidative stress,proteasome inhibition and cytokeratin aggresome（Mallory body-like） formation. Exp Mol Pathol,2006,81（3）：191-201.
[20] Thakur V,Pritchard MT,McMullen MR,et al. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells：role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol,2006,79（6）：1348-1356.
[21] Nieto N. Ethanol and fish oil induce NFkappaB transactivation of the collagen alpha2（I） promoter through lipid peroxidation-driven activation of the PKC-PI3K-Akt pathway. Hepatology,2007,45（6）：1433-1445.
[22] Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology,2009,50（2）：638-644.
[23] 李鑫,王晨,聂娇,等. 酒精性肝炎小鼠肝肠组织变化与内毒素血症的关系探讨. 实用肝脏病杂志,2013,16（3）：254-256.
[24] Rao RK,Seth KA,Sheth P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol,2004,286（6）：G881-G884.
[25] Mutlu E,Keshavarzian A,Engen P,et al. Intestinal dysbiosis： a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res,2009,33（10）：1836-1846.
[26] Forsyth CB,Farhadi A,Jakate SM,et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress,gut leakiness,and liver injury in a rat model of alcoholic steatohepatitis. Alcohol,2009,43（2）：163-172.
[27] Kirpich IA,Solovieva NV,Leikhter SN,et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury：a pilot study. Alcohol,2008,42（8）：675-682.
[28] Elamin E,Jonkers D,Juuti-Uusitalo K,et al. Effects of ethanol and acetaldehyde on tight junction integrity：in vitro study in a three dimensional intestinal epithelial cell culture model. PLoS One,2012,7（4）：e35008.
[29] Li X,Wang C,Nie J,et al. Toll-like receptor 4 increases intestinal permeability through up-regulation of membrane PKC activity in alcoholic steatohepatitis. Alcohol,2013,47（6）：459-465.
[30] Tang Y,Forsyth CB,Farhadi A,et al. Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res,2009,33（7）：1220-1230.
[31] Tang Y,Banan A,Forsyth CB,et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res,2008,32（2）：355-364.
[32] Szabo G,Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol,2010,16（11）：1321-1329.
[33] Zhong W,McClain CJ,Cave M,et al. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol,2010,298（5）：G625-G633.
[34] Voican CS,Perlemuter G,Naveau S. Mechanisms of the inflammatory reaction implicated in alcoholic hepatitis：2011 update. Clin Res Hepatol Gastroenterol,2011,35（6-7）：465-474.
[35] Ohtake T,Saito H,Hosoki Y,et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res,2007,31（1 Suppl）：S2-S8.
[36] Endo M,Masaki T,Seike M,et al. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c （SREBP-1c）. Exp Biol Med （Maywood）,2007,232（5）：614-621.
[37] Kang L,Sebastian BM,Pritchard MT,et al. Chronic ethanol-induced insulin resistance is associated with macrophage infiltration into adipose tissue and altered expression of adipocytokines. Alcohol Clin Exp Res,2007,31（9）：1581-1588.
[38] Jeong WI,Park O,Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology,2008,134（1）：248-258.
[39] Roychowdhury S,McMullen MR,Pritchard MT,et al. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology,2009,49（4）：1326-1334.
[40] Cohen JI,Roychowdhury S,McMullen MR,et al. Complement and alcoholic liver disease：role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology,2010,139（2）：664-674.
[41] Lemmers A,Moreno C,Gustot T,et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology,2009,49（2）：646-657.
[42] Albano E,Vidali M. Immune mechanisms in alcoholic liver disease. Genes Nutr,2010,5（2）：141-147.
[43] Lian M,Hua J,Sheng L,et al. Prevalence and significance of autoantibodies in patients with alcoholic liver disease. J Dig Dis,2013,14（7）：396-401.
[44] Morales-Ibanez O,Dominguez M,Ki SH,et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology,2013,58（5）：1742-1756.
[45] You M,Rogers CQ. Adiponectin：a key adipokine in alcoholic fatty liver. Exp Biol Med（Maywood）,2009,234（8）：850-859.

酒精性肝病发病机制研究进展^*

Progress in the pathogenesis of alcoholic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[2]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[3]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[4]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[5]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[6]	邱军, 王雪清, 张波, 吕波. 经皮胆道造瘘碎石取石术治疗肝内胆管结石患者疗效分析[J]. 实用肝脏病杂志, 2019, 22(5): 744-747.
[7]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[8]	张微, 史军梅, 王倩. 新生儿发生高胆红素血症危险因素分析[J]. 实用肝脏病杂志, 2019, 22(4): 534-536.
[9]	李芳, 邹桂舟, 叶珺, 郜玉峰. 失代偿期肝硬化并发败血症患者临床特征及其危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 557-560.
[10]	王海舫, 杨大伟, 贾蓓, 张岁, 柳立平, 马文波, 解从君, 刘明书. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化[J]. 实用肝脏病杂志, 2019, 22(3): 381-384.
[11]	刘文博, 张建业, 保积武. ERCP和EST治疗胆总管结石复发危险因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 437-440.
[12]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[13]	张岱,王炳元. 酒精性肝炎的诊断与挑战^*[J]. 实用肝脏病杂志, 2019, 22(2): 153-155.
[14]	孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159.
[15]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.